AMETEK, Inc. (AME) Market Cap & Valuation Ratios
AMETEK, Inc. (AME) has a market cap of $55.0B, a trailing P/E of 35.1 and a price-to-sales ratio of 7.0, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AMEAMETEK, Inc.Follow AME — free
—
Price chart with a free account
- Market cap
- 55.0B
- P/E TTM
- 35.1
- Dividend yield
- 0.5%
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Peers
specialty industrial machinery · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| AME | 55 | 35.1 | 7.2 | 23.0 | 3.3% | +13% | 26% | 14% |
| PH | 111 | 30.9 | 5.5 | 19.8 | 3.5% | +8% | 24% | 18% |
| EMR | 90 | 35.4 | 5.4 | 19.8 | 3.8% | +5% | 19% | 9% |
| ITW | 79 | 25.0 | 5.3 | 18.3 | 3.7% | +4% | 26% | 29% |
| CMI | 71 | 26.4 | 2.2 | 15.0 | 4.7% | +3% | 11% | 16% |
| ROK | 47 | 39.9 | 5.6 | 21.3 | 3.2% | +11% | 23% | 27% |
| OTIS | 29 | 19.3 | 2.4 | 14.7 | 6.0% | +5% | 15% | 98% |
| IR | 29 | 30.2 | 4.0 | 16.3 | 4.3% | +8% | 18% | 8% |
| DOV | 26 | 23.2 | 3.3 | 15.1 | 4.5% | +8% | 17% | 13% |
| XYL | 25 | 25.9 | 3.0 | 14.3 | 3.8% | +5% | 14% | 9% |
| SYM | 24 | — | 8.3 | 569.1 | 3.3% | +21% | 0.0% | — |
| Median of these 10 | 26.4 | 4.7 | 17.3 | 3.8% | +7% | 18% | 16% |
P/E 35.1 vs. a peer median of 26.4; EV/Sales 7.2 vs. 4.7. AME's own P/E sits at the 84th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesSYM has no P/E (earnings not positive) and is left out · hover or tap a dot for values.
AMETEK, Inc. — questions
- What is AMETEK, Inc.'s market cap?
- $55.0B.
- What is AMETEK, Inc.'s P/E ratio?
- 35.1 on trailing twelve-month earnings to 2026-06-30.
- What is AMETEK, Inc.'s price-to-sales ratio?
- 7.0.
Every figure on this page comes from AMETEK, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.